世嘉科技(002796.SZ)高管姚躍文累計減持15萬股 提前完成減持計劃
格隆匯2月17日丨世嘉科技(002796.SZ)公佈,公司於2020年1月10日對外披露了《關於高級管理人員股份減持計劃的預披露公告》,姚躍文因個人資金需求擬於其股份減持計劃對外披露之日起15個交易日後的6個月內(窗口期內不減持),以集中競價交易、大宗交易方式減持本公司股份不超過15萬股(含),計劃減持股份比例不超過公司股份總數的0.0891%(含)。
2020年2月17日收市後,公司收到姚躍文的《關於股份減持計劃實施進展的告知函》,姚躍文累計減持15萬股,本次減持行為與已披露的減持計劃一致,實際減持股份數量未超過計劃減持股份數量,本次姚躍文的股份減持計劃提前實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.